Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lisaftoclax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lisaftoclax overview
Lisaftoclax (APG -2575) is under development for the treatment of B-cell cancers such as relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma, acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), diffuse large B-cell lymphoma, mantle cell lymphoma, chronic myelomonocytic leukemia, myelodysplastic syndrome, waldenstrom macroglobulinemia, T-cell prolymphocytic leukemia (r/r T-PLL), follicular lymphoma, hairy cell leukemia, solid tumors, acute lymphoblastic leukemia, metastatic ER positive, HER2 negative breast cancer, immunoglobulin light-chain (AL) amyloidosis, and systemic lupus erythematosus (SLE). It is administered through oral route in the form of tablet. The drug candidate acts by targeting Bcl-2 protein.
Ascentage Pharma Group International overview
Ascentage Pharma Group International (Ascentage Pharma) is a clinical-stage biopharmaceutical company that primarily focuses on the development of novel therapies for cancers, chronic hepatitis B and age-related diseases. The company specializes in designing inhibitors of protein-protein interactions (PPIs) to restore apoptosis or programmed cell death. Its product portfolio includes clinical drug candidates, such as novel Bcl-2/Bcl-xL inhibitors, IAP and MDM2-p53 pathway candidates, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma’s core drug candidate, Olverembatinib, is used for the treatment of drug-resistant chronic myeloid leukemia (CML). The company’s products are used in the healthcare industry, specifically in the treatment of various diseases including cancers and hepatitis B. The company is currently conducting over 40 Phase I/II clinical trials in the US, Australia, Europe, and China. It has offices in the US, Australia and China. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Lisaftoclax’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
